NewsBenzingaSavers Value Village Narrows FY2026 Adj EPS Guidance from $0.47-$0.53 to $0.48-$0.52 vs $0.49 Est; Narrows FY2026 Sales Guidance from $1.770B-$1.790B to $1.770B-$1.780B vs $1.782B Est Savers Value Village Narrows FY2026 Adj EPS Guidance from $0.47-$0.53 to $0.48-$0.52 vs $0.49 Est; Narrows FY2026 Sales Guidance from $1.770B-$1.790B to $1.770B-$1.780B vs $1.782B Est Benzinga 2026.11.05 22:26 (GMT+0) Open on Benzinga Other news Global-E Online Stock Is Falling Wednesday: What's Going On? Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $6 Stifel Maintains Buy on Ecolab, Raises Price Target to $356 Stifel Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $26 Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients
Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease
Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients